Skip to product information
Cagrilintide (5mg)
  • Cagrilintide (5mg)
Cagrilintide (5mg)

Cagrilintide (5mg)

$190.00 USD
In stock

Cagrilintide is a long-acting amylin analog that reinforces the body’s natural “I’m full” signal, helping reduce meal size and energy intake. In clinical studies, once-weekly cagrilintide produced dose-dependent weight loss and was well-tolerated.

Quantity Selection
Product Description

Cagrilintide 5mg

Long-Acting Amylin Analog for Advanced Appetite Control

Formulation
5mg Cagrilintide per vial (lyophilized powder) – single peptide

Classification: Prescription Only – Requires Provider Consultation & Approval

Why Cagrilintide?

Because precise satiety control changes everything. Cagrilintide is a long-acting amylin analog that reinforces the body’s natural “I’m full” signal, helping reduce meal size and energy intake. In clinical studies, once-weekly cagrilintide produced dose-dependent weight loss and was well-tolerated. When paired with a GLP-1 (the “CagriSema” combo), trials show greater weight reduction than either alone. The LancetPubMedScienceDirectNew England Journal of Medicine

  • Amylin pathway = earlier satiation: Acts centrally (area postrema and related nuclei) to promote meal termination and moderate gastric emptying. ScienceDirectPMC

  • Once-weekly design: Engineered for weekly subcutaneous dosing via acylation/long-acting PK. ACS Publications

  • Synergy option: Co-administration with semaglutide (CagriSema) delivered ~20–23% mean weight loss at 68 weeks in Phase 3, with consistent metabolic improvements. (For qualified patients under clinician guidance.) American College of CardiologyNew England Journal of MedicinePR Newswire

General Dosing Guidance (Based on 2mL Dilution = 200 Units)

  • Typical Range: 10–50 units once weekly (0.25–1.25 mg/week).

  • Timing: Evening, subcutaneous injection.

  • Peptide Content Per Unit: 0.025 mg cagrilintide per unit (5 mg ÷ 200 units).
    Follow your prescriber’s protocol. Start low, increase only if well-tolerated. The Lancet

Recommended Protocol Options

1-Month Appetite-Reset Protocol

  • Dose: 10–20 units once weekly (0.25–0.5 mg/week).

  • Best For: Initial satiety training, portion control, GI tolerance check.

  • Evidence: Early-phase, once-weekly cagrilintide produced dose-dependent weight reductions and good tolerability. The LancetPubMed

3-Month Satiety & Metabolic Protocol

  • Dose: 20–40 units once weekly (0.5–1.0 mg/week).

  • Best For: Sustained appetite control with measurable weight and waist changes; consider pairing with lifestyle/GLP-1 under supervision.

  • Evidence: Co-administration with semaglutide (CagriSema) outperformed monotherapy in randomized trials. ScienceDirect

6-Month Comprehensive Program

  • Dose: 30–50 units once weekly (0.75–1.25 mg/week), titrated to the lowest effective dose.

  • Best For: Long-term weight management and metabolic stability with periodic review (q4–6 weeks).

  • Evidence: Phase 2 and Phase 3 programs demonstrate robust, sustained weight loss with weekly amylin analog therapy and enhanced results when combined with GLP-1s. The LancetAmerican College of Cardiology

No mandatory “reset” is required; reassess dose and tolerability monthly. Do not start multiple new agents at once—stagger to identify benefit and tolerance. The Lancet

What’s Included With Every Order

  • 1 × vial Cagrilintide 5 mg

  • Reconstitution guidance (for provider-directed use)

  • Optional add-ons: bacteriostatic water, insulin syringes, sharps disposal (where permitted)

  • Printed dosing & titration guide

  • Telehealth consultation + provider support (where available)

Summary

Cagrilintide amplifies satiety at the amylin axis, giving you a precise, once-weekly lever for portion control and weight management. With a clean mechanism, flexible titration, and proven synergy alongside GLP-1s, it’s a powerful option for programs that demand clinical rigor and real-world adherence. The LancetScienceDirect

Key References

  • Enebo LB, et al. Lancet (2021): Randomized phase 1b/2—dose-dependent weight loss with weekly cagrilintide; favorable tolerability. The Lancet

  • Frias JP, et al. Lancet (2023): Co-administered semaglutide + cagrilintide showed superior efficacy vs. comparators. The LancetScienceDirect

  • Davies MJ, et al. NEJM (2025): Phase 3 REDEFINE—CagriSema achieved ~20–23% mean weight loss at 68 weeks. New England Journal of MedicineAmerican College of Cardiology

  • Kruse T, et al. J Med Chem (2021): Development of long-acting cagrilintide; weekly SC dosing rationale. ACS Publications

  • Bower RL, et al. (2016) & Osto M, et al. (2007): Amylin’s central satiation biology and receptor pharmacology. PMC
Directions For Use

Cagrilintide 5mg

Long-Acting Amylin Analog for Advanced Appetite Control

Formulation
5mg Cagrilintide per vial (lyophilized powder) – single peptide

Classification: Prescription Only – Requires Provider Consultation & Approval

Why Cagrilintide?

Because precise satiety control changes everything. Cagrilintide is a long-acting amylin analog that reinforces the body’s natural “I’m full” signal, helping reduce meal size and energy intake. In clinical studies, once-weekly cagrilintide produced dose-dependent weight loss and was well-tolerated. When paired with a GLP-1 (the “CagriSema” combo), trials show greater weight reduction than either alone. The LancetPubMedScienceDirectNew England Journal of Medicine

  • Amylin pathway = earlier satiation: Acts centrally (area postrema and related nuclei) to promote meal termination and moderate gastric emptying. ScienceDirectPMC

  • Once-weekly design: Engineered for weekly subcutaneous dosing via acylation/long-acting PK. ACS Publications

  • Synergy option: Co-administration with semaglutide (CagriSema) delivered ~20–23% mean weight loss at 68 weeks in Phase 3, with consistent metabolic improvements. (For qualified patients under clinician guidance.) American College of CardiologyNew England Journal of MedicinePR Newswire

General Dosing Guidance (Based on 2mL Dilution = 200 Units)

  • Typical Range: 10–50 units once weekly (0.25–1.25 mg/week).

  • Timing: Evening, subcutaneous injection.

  • Peptide Content Per Unit: 0.025 mg cagrilintide per unit (5 mg ÷ 200 units).
    Follow your prescriber’s protocol. Start low, increase only if well-tolerated. The Lancet

Recommended Protocol Options

1-Month Appetite-Reset Protocol

  • Dose: 10–20 units once weekly (0.25–0.5 mg/week).

  • Best For: Initial satiety training, portion control, GI tolerance check.

  • Evidence: Early-phase, once-weekly cagrilintide produced dose-dependent weight reductions and good tolerability. The LancetPubMed

3-Month Satiety & Metabolic Protocol

  • Dose: 20–40 units once weekly (0.5–1.0 mg/week).

  • Best For: Sustained appetite control with measurable weight and waist changes; consider pairing with lifestyle/GLP-1 under supervision.

  • Evidence: Co-administration with semaglutide (CagriSema) outperformed monotherapy in randomized trials. ScienceDirect

6-Month Comprehensive Program

  • Dose: 30–50 units once weekly (0.75–1.25 mg/week), titrated to the lowest effective dose.

  • Best For: Long-term weight management and metabolic stability with periodic review (q4–6 weeks).

  • Evidence: Phase 2 and Phase 3 programs demonstrate robust, sustained weight loss with weekly amylin analog therapy and enhanced results when combined with GLP-1s. The LancetAmerican College of Cardiology

No mandatory “reset” is required; reassess dose and tolerability monthly. Do not start multiple new agents at once—stagger to identify benefit and tolerance. The Lancet

What’s Included With Every Order

  • 1 × vial Cagrilintide 5 mg

  • Reconstitution guidance (for provider-directed use)

  • Optional add-ons: bacteriostatic water, insulin syringes, sharps disposal (where permitted)

  • Printed dosing & titration guide

  • Telehealth consultation + provider support (where available)

Summary

Cagrilintide amplifies satiety at the amylin axis, giving you a precise, once-weekly lever for portion control and weight management. With a clean mechanism, flexible titration, and proven synergy alongside GLP-1s, it’s a powerful option for programs that demand clinical rigor and real-world adherence. The LancetScienceDirect

Key References

  • Enebo LB, et al. Lancet (2021): Randomized phase 1b/2—dose-dependent weight loss with weekly cagrilintide; favorable tolerability. The Lancet

  • Frias JP, et al. Lancet (2023): Co-administered semaglutide + cagrilintide showed superior efficacy vs. comparators. The LancetScienceDirect

  • Davies MJ, et al. NEJM (2025): Phase 3 REDEFINE—CagriSema achieved ~20–23% mean weight loss at 68 weeks. New England Journal of MedicineAmerican College of Cardiology

  • Kruse T, et al. J Med Chem (2021): Development of long-acting cagrilintide; weekly SC dosing rationale. ACS Publications

  • Bower RL, et al. (2016) & Osto M, et al. (2007): Amylin’s central satiation biology and receptor pharmacology. PMC
Ingredients

Cagrilintide 5mg

Long-Acting Amylin Analog for Advanced Appetite Control

Formulation
5mg Cagrilintide per vial (lyophilized powder) – single peptide

Classification: Prescription Only – Requires Provider Consultation & Approval

Why Cagrilintide?

Because precise satiety control changes everything. Cagrilintide is a long-acting amylin analog that reinforces the body’s natural “I’m full” signal, helping reduce meal size and energy intake. In clinical studies, once-weekly cagrilintide produced dose-dependent weight loss and was well-tolerated. When paired with a GLP-1 (the “CagriSema” combo), trials show greater weight reduction than either alone. The LancetPubMedScienceDirectNew England Journal of Medicine

  • Amylin pathway = earlier satiation: Acts centrally (area postrema and related nuclei) to promote meal termination and moderate gastric emptying. ScienceDirectPMC

  • Once-weekly design: Engineered for weekly subcutaneous dosing via acylation/long-acting PK. ACS Publications

  • Synergy option: Co-administration with semaglutide (CagriSema) delivered ~20–23% mean weight loss at 68 weeks in Phase 3, with consistent metabolic improvements. (For qualified patients under clinician guidance.) American College of CardiologyNew England Journal of MedicinePR Newswire

General Dosing Guidance (Based on 2mL Dilution = 200 Units)

  • Typical Range: 10–50 units once weekly (0.25–1.25 mg/week).

  • Timing: Evening, subcutaneous injection.

  • Peptide Content Per Unit: 0.025 mg cagrilintide per unit (5 mg ÷ 200 units).
    Follow your prescriber’s protocol. Start low, increase only if well-tolerated. The Lancet

Recommended Protocol Options

1-Month Appetite-Reset Protocol

  • Dose: 10–20 units once weekly (0.25–0.5 mg/week).

  • Best For: Initial satiety training, portion control, GI tolerance check.

  • Evidence: Early-phase, once-weekly cagrilintide produced dose-dependent weight reductions and good tolerability. The LancetPubMed

3-Month Satiety & Metabolic Protocol

  • Dose: 20–40 units once weekly (0.5–1.0 mg/week).

  • Best For: Sustained appetite control with measurable weight and waist changes; consider pairing with lifestyle/GLP-1 under supervision.

  • Evidence: Co-administration with semaglutide (CagriSema) outperformed monotherapy in randomized trials. ScienceDirect

6-Month Comprehensive Program

  • Dose: 30–50 units once weekly (0.75–1.25 mg/week), titrated to the lowest effective dose.

  • Best For: Long-term weight management and metabolic stability with periodic review (q4–6 weeks).

  • Evidence: Phase 2 and Phase 3 programs demonstrate robust, sustained weight loss with weekly amylin analog therapy and enhanced results when combined with GLP-1s. The LancetAmerican College of Cardiology

No mandatory “reset” is required; reassess dose and tolerability monthly. Do not start multiple new agents at once—stagger to identify benefit and tolerance. The Lancet

What’s Included With Every Order

  • 1 × vial Cagrilintide 5 mg

  • Reconstitution guidance (for provider-directed use)

  • Optional add-ons: bacteriostatic water, insulin syringes, sharps disposal (where permitted)

  • Printed dosing & titration guide

  • Telehealth consultation + provider support (where available)

Summary

Cagrilintide amplifies satiety at the amylin axis, giving you a precise, once-weekly lever for portion control and weight management. With a clean mechanism, flexible titration, and proven synergy alongside GLP-1s, it’s a powerful option for programs that demand clinical rigor and real-world adherence. The LancetScienceDirect

Key References

  • Enebo LB, et al. Lancet (2021): Randomized phase 1b/2—dose-dependent weight loss with weekly cagrilintide; favorable tolerability. The Lancet

  • Frias JP, et al. Lancet (2023): Co-administered semaglutide + cagrilintide showed superior efficacy vs. comparators. The LancetScienceDirect

  • Davies MJ, et al. NEJM (2025): Phase 3 REDEFINE—CagriSema achieved ~20–23% mean weight loss at 68 weeks. New England Journal of MedicineAmerican College of Cardiology

  • Kruse T, et al. J Med Chem (2021): Development of long-acting cagrilintide; weekly SC dosing rationale. ACS Publications

  • Bower RL, et al. (2016) & Osto M, et al. (2007): Amylin’s central satiation biology and receptor pharmacology. PMC
Disclaimer

Cagrilintide 5mg

Long-Acting Amylin Analog for Advanced Appetite Control

Formulation
5mg Cagrilintide per vial (lyophilized powder) – single peptide

Classification: Prescription Only – Requires Provider Consultation & Approval

Why Cagrilintide?

Because precise satiety control changes everything. Cagrilintide is a long-acting amylin analog that reinforces the body’s natural “I’m full” signal, helping reduce meal size and energy intake. In clinical studies, once-weekly cagrilintide produced dose-dependent weight loss and was well-tolerated. When paired with a GLP-1 (the “CagriSema” combo), trials show greater weight reduction than either alone. The LancetPubMedScienceDirectNew England Journal of Medicine

  • Amylin pathway = earlier satiation: Acts centrally (area postrema and related nuclei) to promote meal termination and moderate gastric emptying. ScienceDirectPMC

  • Once-weekly design: Engineered for weekly subcutaneous dosing via acylation/long-acting PK. ACS Publications

  • Synergy option: Co-administration with semaglutide (CagriSema) delivered ~20–23% mean weight loss at 68 weeks in Phase 3, with consistent metabolic improvements. (For qualified patients under clinician guidance.) American College of CardiologyNew England Journal of MedicinePR Newswire

General Dosing Guidance (Based on 2mL Dilution = 200 Units)

  • Typical Range: 10–50 units once weekly (0.25–1.25 mg/week).

  • Timing: Evening, subcutaneous injection.

  • Peptide Content Per Unit: 0.025 mg cagrilintide per unit (5 mg ÷ 200 units).
    Follow your prescriber’s protocol. Start low, increase only if well-tolerated. The Lancet

Recommended Protocol Options

1-Month Appetite-Reset Protocol

  • Dose: 10–20 units once weekly (0.25–0.5 mg/week).

  • Best For: Initial satiety training, portion control, GI tolerance check.

  • Evidence: Early-phase, once-weekly cagrilintide produced dose-dependent weight reductions and good tolerability. The LancetPubMed

3-Month Satiety & Metabolic Protocol

  • Dose: 20–40 units once weekly (0.5–1.0 mg/week).

  • Best For: Sustained appetite control with measurable weight and waist changes; consider pairing with lifestyle/GLP-1 under supervision.

  • Evidence: Co-administration with semaglutide (CagriSema) outperformed monotherapy in randomized trials. ScienceDirect

6-Month Comprehensive Program

  • Dose: 30–50 units once weekly (0.75–1.25 mg/week), titrated to the lowest effective dose.

  • Best For: Long-term weight management and metabolic stability with periodic review (q4–6 weeks).

  • Evidence: Phase 2 and Phase 3 programs demonstrate robust, sustained weight loss with weekly amylin analog therapy and enhanced results when combined with GLP-1s. The LancetAmerican College of Cardiology

No mandatory “reset” is required; reassess dose and tolerability monthly. Do not start multiple new agents at once—stagger to identify benefit and tolerance. The Lancet

What’s Included With Every Order

  • 1 × vial Cagrilintide 5 mg

  • Reconstitution guidance (for provider-directed use)

  • Optional add-ons: bacteriostatic water, insulin syringes, sharps disposal (where permitted)

  • Printed dosing & titration guide

  • Telehealth consultation + provider support (where available)

Summary

Cagrilintide amplifies satiety at the amylin axis, giving you a precise, once-weekly lever for portion control and weight management. With a clean mechanism, flexible titration, and proven synergy alongside GLP-1s, it’s a powerful option for programs that demand clinical rigor and real-world adherence. The LancetScienceDirect

Key References

  • Enebo LB, et al. Lancet (2021): Randomized phase 1b/2—dose-dependent weight loss with weekly cagrilintide; favorable tolerability. The Lancet

  • Frias JP, et al. Lancet (2023): Co-administered semaglutide + cagrilintide showed superior efficacy vs. comparators. The LancetScienceDirect

  • Davies MJ, et al. NEJM (2025): Phase 3 REDEFINE—CagriSema achieved ~20–23% mean weight loss at 68 weeks. New England Journal of MedicineAmerican College of Cardiology

  • Kruse T, et al. J Med Chem (2021): Development of long-acting cagrilintide; weekly SC dosing rationale. ACS Publications

  • Bower RL, et al. (2016) & Osto M, et al. (2007): Amylin’s central satiation biology and receptor pharmacology. PMC

Physician Backed

Made In America

Clinically Trusted

Complementary Products